 | |
| Clinical data | |
|---|---|
| Other names | PNU-95,666 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13N3O |
| Molar mass | 203.245 g·mol−1 |
| 3D model (JSmol) | |
| |
Sumanirole (PNU-95,666) is a highlyselectiveD2 receptorfull agonist, the first of its kind to be discovered.[1][2][3] It was developed for the treatment ofParkinson's disease andrestless leg syndrome. While it has never been approved for medical use[4][5] it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action.[3]
In 2004,Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.[6]
